Pharming Group NV Announces Leniolisib Results Call Transcript
Ladies and gentlemen, good afternoon or good morning. And welcome to this analyst conference call about the pivotal data that was released yesterday in our press release. And today, with me here is our colleague, our Chief Medical Officer, Dr. Anurag Relan, who can take you through the data in a little bit more detail and talk a little bit more about the APDS disease. But before we do that, I would like to draw your attention to this slide with the forward-looking statements.
As you know, we're a listed company, obviously, and I have to make this -- warn you against forward-looking statements that circumstances and plans may change, as we all know. And having said that, I would like to then briefly introduce this. So the history here of leniolisib is that in August 2019, we in-licensed leniolisib from Novartis, and leniolisib is -- was under -- is under development for the treatment of APDS, activated phosphoinositide 3-kinase delta syndrome, which is a rare primary immune deficiency caused by genetic mutations,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
